Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The custom manufacturing and technology business of Royal DSM, DSM Pharmaceutical Products, has signed a licensing deal with Amgen for the use of DSM's XD high cell density process patents.
Subscribe to our email newsletter
XD technology is an intensified cell culture process with typical XD titer improvement of 8-10 times and is applicable for multiple biological products such as proteins, fusion proteins and antibodies.
The technology has been employed across a range of mammalian cell systems.
DSM Biologics president Karen King said, "We believe our proprietary XD technology will play an important role in the next generation of biopharmaceutical manufacturing."
Financial details of the transaction were not revealed.
DSM Pharmaceutical Products president and CEO Alexander Wessels said, "DSM continuously strives to provide its clients with added value through our innovative service and technology offerings."